4 results
Approved WMOCompleted
Main objective: To assess the effect of CK-2127107 versus placebo on respiratory function in patients with ALS.
Approved WMOCompleted
The key objective of this study is to assess next-day residual effects of MK-4305 (20 and 40 mg) via driving performance after 1 day of dosing and after 8 days of dosing.
Approved WMOCompleted
The purpose of this study is to evaluate whether the new drug reldesemtiv is effective and safe in patients with ALS. The primary objective is to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS.The secondary objectives…
Approved WMOCompleted
To assess the long-term safety and tolerability of reldesemtiv in patients with ALS